Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma
- 5 February 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (6) , 1767-1778
Abstract
Purpose Approximately, 45–65% stage I non-small cell lung cancer (NSCLC) patients with surgical resection relapse within 5 years. Therefore, it is urgent to identify the predictors involved in the relapse of stage I NSCLC. Methods/patients Targeted sequencing was used to examine the mutation of tumor tissues and matched adjacent normal tissues from 35 patients with stage I lung adenocarcinoma (LUAD). Then, tissue microarrays containing tumor tissues from 149 stage I LUAD patients were used to assess protein expression of frequently mutated genes by immunohistochemistry. COX regression model was used to evaluate the impacts of frequently mutated genes and their protein expression on relapse-free survival (RFS) in stage I LUAD. Results and conclusions Three hundred and twenty-nine non-synonymous somatic variants were identified in 161 genes among these 35 patients. EGFR, TP53, LRP1B, RBM10, KRAS, NTRK3, RB1, ALK, APC, FAT2, KEAP1, MED12 and MLL3 were described as frequently mutated genes with prevalence more than 10%. Patients harboring KRAS mutation had more relapse in 1 year after surgical resection. For the expression of these frequently mutated genes in 149 stage I patients, multivariate Cox regression analyses showed that the expression of RBM10 was positively associated with RFS in all patients (HR 0.40, 95% CI 0.15–1.0, p = 0.052), and the expression of APC was negative associated with RFS in patients with EGFR mutations (HR 3.10, 95% CI 1.54–6.26, p = 0.002). Stage I LUAD patients with KRAS mutation or low RBM10 expression are inclined to receive more positive intervention rather than just disease surveillance.Keywords
Funding Information
- Natural Science Foundation of China (8207112270)
This publication has 47 references indexed in Scilit:
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung CancersThe Annals of Thoracic Surgery, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Long‐term survival in TARP syndrome and confirmation of RBM10 as the disease‐causing geneAmerican Journal of Medical Genetics Part A, 2011
- Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean populationLung Cancer, 2007
- Prognostic factors for survival of stage I nonsmall cell lung cancer patientsCancer, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine CytokinesCell Cycle, 2005
- APC mutations are infrequent but present in human lung cancerCancer Letters, 2004
- Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung CancerJapanese Journal of Clinical Oncology, 2002
- Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survivalOncogene, 2001